Marketing-authorisation holder · Ireland
Ptc Therapeutics International Limited
18 medicines in 6 countries, as authorisation holder and marketer.
Loading your page…
Loading your page…
Marketing-authorisation holder · Ireland
18 medicines in 6 countries, as authorisation holder and marketer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
18 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| SEPHIENCE250 mg / sachet · Powder | Sepiapterin | Canada | Marketed | 2025 |
| SEPHIENCE1000 mg / sachet · Powder | Sepiapterin | Canada | Marketed | 2025 |
| Sephience | Sepiapterin | EU (EMA) | Authorised | 2025 |
| Sephience 1.000 mg poeder voor oraal gebruik in sachetPoeder voor oraal gebruik | Sepiapterin | Netherlands | Authorised | 2025 |
| SEPHIENCE 1000 MG POLVO ORAL EN SOBRE1000 mg · Polvo oral en sobre | Sepiapterin | Spain | Authorised | 2026 |
| Sephience 250 mg poeder voor oraal gebruik in sachetPoeder voor oraal gebruik | Sepiapterin | Netherlands | Authorised | 2025 |
| SEPHIENCE 250 MG POLVO ORAL EN SOBRE250 mg · Polvo oral en sobre | Sepiapterin | Spain | Authorised | 2026 |
| TRANSLARNA 1000 MG GRANULADO PARA SUSPENSION ORAL1000 mg · Granulado para suspensión oral | Ataluren | Spain | Authorised | 2014 |
| TRANSLARNA 125 MG GRANULADO PARA SUSPENSION ORAL125 mg · Granulado para suspensión oral | Ataluren | Spain | Authorised | 2014 |
| TRANSLARNA 250 MG GRANULADO PARA SUSPENSION ORAL250 mg · Granulado para suspensión oral | Ataluren | Spain | Authorised | 2014 |
| Upstaza | Eladocagene exuparvovec | EU (EMA) | Authorised | 2022 |
| UPSTAZASoluzione per infusione | Eladocagene exuparvovec | Italy | Authorised | |
| UPSTAZA 2,8 × 10E11 GENOMAS VECTORIALES (VG)/0,5 ML PARA SOLUCION PARA PERFUSION5,6 10e11 vg/ml · Solución para perfusión | Eladocagene exuparvovec | Spain | Authorised | 2022 |
| Upstaza 2,8 x 10^11 vg/0.5 ml, oplossing voor infusieOplossing voor infusie | Eladocagene exuparvovec | Netherlands | Authorised | 2022 |
| Translarna | Ataluren | EU (EMA) | Cancelled | 2014 |
| TRANSLARNA 1000 mg1000mg · Granule pt. susp. orala | Ataluren | Romania | unknown | |
| TRANSLARNA 125 mg125mg · Granule pt. susp. orala | Ataluren | Romania | unknown | |
| TRANSLARNA 250 mg250mg · Granule pt. susp. orala | Ataluren | Romania | unknown |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 6 | 6 | 0 | CompaniesAll medicines |
| European Union (EMA) | 3 | 2 | 1 | CompaniesAll medicines |
| Netherlands | 3 | 3 | 0 | CompaniesAll medicines |
| Romania | 3 | 0 | 3 | CompaniesAll medicines |
| Canada | 2 | 2 | 0 | CompaniesAll medicines |
| Italy | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of France, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.